Clinical trials: Camrelizumab
Lung Cancer
Cryoablation Combined With Camrelizumab and Apatinib for Multiprimary Lung Cancer
Objective: This study is to observe the safety and therapeutic effect of cryoablation combined with pd-1 antibody immunotherapy and anti-angiogenesis therapy in multiple primary lung cancer (MPLC) patients.
- Trial name
- CCA-MPLC (NCT04201990)
- Testing
- Camrelizumab and Apatinib
- Volunteers
- 20 people
- Sponsor
- ShiYue Li
Head and Neck Squamous Cell Carcinoma
Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCC
This study is a single arm phase II trial including 53 patients with T2N2-3M0、T3-4N0-3M0（III-IV） head and neck squamous cell carcinoma (HNSCC) eligible for resection, who receive neo-adjvuant Camrelizumab combined with cisplatin…
- Trial name
- NCT04826679
- Testing
- Camrelizumab, nab-paclitaxel, cisplatin
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Sun Yat-sen University
Head and Neck Squamous Cell Carcinoma
Camrelizumab Combined With Apatinib Mesylate for Head and Neck Squamous Cell Carcinoma
This is a prospective, open-labelled study to evaluate the efficacy and safety of camrelizumab combined with apatinib mesylate in the induction treatment of patients with locally advanced head and neck squamous cell carcinoma who…
- Trial name
- IMplus (NCT04440917)
- Testing
- Camrelizumab, Apatinib Mesylate
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Hepatocellular Carcinoma
SHR-1210 Plus Apatinib in Patients With Hepatocellular Carcinoma After Surgery
SHR-1210 is a humanized anti-PD1 Immunoglobulin G4 (IgG4) monoclonal antibody. This is an open- label，single center ，non-randomized ，Single Arm Exploratory Study .
- Trial name
- NCT03722875
- Testing
- SHR-1210, apatinib
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Shanghai Zhongshan Hospital
Classical Hodgkin Lymphoma
Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma
This is a prospective single-arm, multi-center and phase II clinical trial to observe the efficacy and safety of Camrelizumab combined with AVD in the first-line treatment for patients with advanced classical Hodgkin's lymphoma.
- Trial name
- NCT04067037
- Testing
- Camrelizumab, Epirubicin, Vincristine
- Where
- 3 sites in China
- Volunteers
- 60 people
- Sponsor
- Henan Cancer Hospital
HCC - Hepatocellular Carcinoma, Chinese Herbal Medicine
Shuganhuazhuo Formula for Advanced Hepatocellular Carcinoma With Damp-Heat Syndrome
Primary liver cancer is a malignant tumor with a very poor prognosis. Hepatocellular carcinoma(HCC) accounts for approximately 80% of cases.
- Conditions
- HCC - Hepatocellular Carcinoma, Chinese Herbal Medicine, ICG (Indocyanine Green), Overall Survival (All-cause Mortality)
- Trial name
- DAWNbreak-120 (NCT07691645)
- Testing
- Shuganhuazhuo Formula, Targeted therapy, Immunotherapy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Xiang-Qian
Advanced Hepatocellular Carcinoma (HCC)
Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment
To evaluate the efficacy and immune microenvironment changes in advanced hepatocellular carcinoma (HCC) patients receiving different first-line immunotherapy.
- Trial name
- HCC-IM-1 (NCT07147101)
- Testing
- Sintilimab, Bevacizumab Biosimilar, Camrelizumab
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Fudan University
Her-2 Negative Breast Cancer, HRR Gene Mutation
Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation
This study is to evaluate the efficacy and safety of combination of Camrelizumab (Immunotherapy, PD-1 inhibitor), Fluzoparib (PARP inhibitor) and Nab-paclitaxel in neoadjuvant therapy of Her-2 negative breast cancer patients with…
- Trial name
- IMPARP (NCT05761470)
- Testing
- Camrelizumab, Fluzoparib, Nab-paclitaxel
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Ying Lin
Gastric Cancer
The Safety and Efficacy of PD-1 Monoantrapical Chemotherapy in the Treatment of Local Advanced Stomach Cancer
To explore the safety and efficacy of local advanced stomach cancer patients receiving new complementary treatment of PD-1 monoantiotherapy before surgery
- Trial name
- NCT05000554
- Testing
- Neoadjuvant Therapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The First Hospital of Jilin University
Nasopharyngeal Carcinoma
Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
This is an Open Label, Non-Inferiority, Multicenter, Randomized Phase 3 Trial aimed to investigate the impact of reduced-dose radiotherapy in combination with chemotherapy and immunotherapy on patients' prognosis and complication…
- Trial name
- NCT06239727
- Testing
- PD-1 blocking antibody, Gemcitabine, Cisplatin (80 mg/m2)
- Where
- 26 sites in China
- Volunteers
- 593 people
- Sponsor
- Sun Yat-sen University
Adrenal Cortical Carcinoma, Adrenal Cortical Cancer
Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma
Adrenocortical carcinoma (ACC) is a rare aggressive malignant tumor. According to the literature, the 5-year survival rate of ACC is 12%-47%.
- Conditions
- Adrenal Cortical Carcinoma, Adrenal Cortical Cancer, Adrenal Cancer
- Trial name
- NCT06831175
- Testing
- Camrelizumab, Apatinib, mitotane
- Where
- China
- Volunteers
- 28 people
- Sponsor
- West China Hospital
Esophageal Neoplasms
PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer
The treatment efficacy for stage IVb esophageal cancer has been improved through chemotherapy combined with immunotherapy recently.
- Trial name
- NCT06086457
- Testing
- Radiation, TP or PF regimen depended on investigator's choice., PD-1 inhibitor
- Where
- China
- Volunteers
- 436 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Non-small Cell Lung Cancer Stage III
Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy
Patients with stage III non-small-cell lung cancer initially evaluated as unresectable are selected for the program, who are remained unresectable after 2-4 cycles of conversion chemotherapy combined with immune checkpoint…
- Trial name
- NCT06031597
- Testing
- radiotherapy, Platinum-Based Drug, Immunotherapy
- Volunteers
- 105 people
- Sponsor
- Zhejiang Cancer Hospital
Non Small Cell Lung Cancer
Anti-CTLA-4 Antibody Followed by Anti-PD-1 Antibody in Recurrent or Metastatic NSCLC
Immunotherapy has made rapid progress in melanoma, Hodgkin's lymphoma, non-small cell lung cancer, and bladder cancer, etc. Preclinical data suggested that the use of anti-PD-1 antibody in combination with CTLA-4 receptor…
- Trial name
- SEQUENCE (NCT03527251)
- Testing
- Ipilimumab, SHR-1210
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
Study on the Effectiveness and Safety of Carrelizumab Combined With Apatinib Mesylate and Radiotherapy in the Treatment of Advanced Liver Cancer
Literature has shown that radiotherapy can promote tumor antigen presentation, mobilize and activate T cells by enhancing activation signals and blocking inhibitory signals.
- Trial name
- NCT04523662
- Testing
- Camrelizumab Apatinib Mesylas
- Volunteers
- 27 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
Efficacy and Safty of Camrelizumab Plus S-1 Maintenance After First-line Induction Chemotherapy for GC
The Neoadjuvant Treatment of Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma.
In this study, We investigated the efficacy and safty of camrelizumab combined with S-1 maintenance after first-line induction chemotherapy for GC.
- Trial name
- NCT05170542
- Testing
- Camrelizumab+S-1
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Peking Union Medical College Hospital
Non-squamous Non-small-cell Lung Cancer, Brain Metastases
Camrelizumab With AC in Patients With Brain Metastases of Driven Gene-negative,NSCLC
The primary hypothesis is that camrelizumab in combination with pemetrexed/ carboplatin will present a better efficacy for treatment of first line metastatic non-squamous non-small cell lung cancer and minimize the risk of…
- Trial name
- CAP-BRAIN (NCT04211090)
- Testing
- Camrelizumab, Pemetrexed, Carboplatin
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Sun Yat-sen University
Esophageal Neoplasms, Esophageal Diseases
Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.
This is a prospective single-arm exploratory clinical study. The efficacy and safety of camrelizumab combined with chemoradiotherapy and camrelizumab combined with chemotherapy were evaluated in patients with advanced esophageal…
- Conditions
- Esophageal Neoplasms, Esophageal Diseases, Digestive System Neoplasms
- Trial name
- NCT05624099
- Testing
- camrelizumab, Paclitaxel drugs, Platinum drug
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Fujian Cancer Hospital
Esophageal Cancer
Combination of Radiotherapy and SHR-1210 to Treat Patients With ESCC
SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody. This is an open-label，single center ，non-randomized ，Single Arm Exploratory Study .
- Trial name
- NCT03222440
- Testing
- SHR-1210
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Esophageal Cancer
A Real-world Study Evaluating the Usage of Camrelizumab in Chinese Patients With Advanced Esophageal Cancer
The trial is a multi-center, open, observational registration study, which aims to evaluate the safety and efficacy of Camrelizumab (anti-PD-1 antibody) in the treatment of Chinese patients with advanced esophageal cancer in the…
- Trial name
- NCT04616040
- Testing
- Camrelizumab
- Where
- China
- Volunteers
- 1,030 people
- Sponsor
- Peking University